The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Investigating the clinical and molecular characteristics of class II and III BRAF mutations and their response to anti-EGFR therapy in MSS CRC: A comprehensive analysis.
 
Ibrahim Halil Sahin
Consulting or Advisory Role - GlaxoSmithKline; Guardant Health; Seagen
 
Joanne Xiu
Employment - Caris Life Sciences
 
Moh'd Khushman
Stock and Other Ownership Interests - Cardiff Oncology
Consulting or Advisory Role - Abbvie; bristol-myers squibb; Cardinal Health; Elevar Therapeutics; Exelixis; Muerus; TriSalus Life Sciences
Speakers' Bureau - Caris Life Sciences
Research Funding - Abbvie (Inst); FOGPharma (Inst); IgM Biosciences (Inst); Torl Biotherapeutics (Inst)
 
Emily Palumbo
No Relationships to Disclose
 
Benjamin Weinberg
Employment - Apple (I)
Stock and Other Ownership Interests - Apple (I)
Honoraria - Primum
Consulting or Advisory Role - Agenus; AstraZeneca/Daiichi Sankyo; Bayer; DoMore Diagnostics; Foundation Medicine; Merus NV; Regeneron
Speakers' Bureau - Bayer; Daiichi Sankyo/Astra Zeneca; Merus NV; Natera; Seagen; Sirtex Medical; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); BioXCel therapeutics (Inst); Immune System Key (Inst); Ipsen (Inst); Merck (Inst)
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - Merus NV
 
Sanjay Goel
Stock and Other Ownership Interests - Johnson and Johnson; Merck; Moderna Therapeutics
Honoraria - GlaxoSmithKline
Research Funding - Amgen (Inst); Deciphera (Inst); Dragonfly Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); Xilio Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - I have a patent with a co-inventor, John Mariadason, Ph.D, entitled "Method Of Determining The Sensitivity Of Cancer Cells To EGFR Inhibitors Including Cetuximab, Panitumumab And Erlotinib.", Patent No. 20090258364
 
Mehmet Akce
Consulting or Advisory Role - AstraZeneca; Curio Science; Eisai; Eisai; Eisai; Eisai; Exelixis; Genentech; GlaxoSmithKline; GlaxoSmithKline; Incyte; Ipsen; Isofol Medical; QED Therapeutics; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Eisai (Inst); Eisai (Inst); IMPAC Medical Systems (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Polaris (Inst); ProDa (Inst); RedHill Biopharma (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst); Xencor (Inst)
 
Aatur Singhi
No Relationships to Disclose
 
Vikram Gorantla
No Relationships to Disclose
 
Emil Lou
Stock and Other Ownership Interests - Ryght
Honoraria - Boston Scientific; Daiichi Sankyo/UCB Japan (Inst); GlaxoSmithKline; Novocure
Consulting or Advisory Role - Boston Scientific; Novocure; Novocure; Novocure; Novocure
Research Funding - Intima; Novocure
Travel, Accommodations, Expenses - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences; Minnetronix Medical; NomoCan
 
Anup Kasi
Consulting or Advisory Role - Cardinal Health; Ipsen
Research Funding - Ability Pharma (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Cardiff Oncology (Inst); Cend Therapeutics (Inst); FibroGen (Inst); Geistlich Pharma (Inst); Novocure (Inst); Rafael Pharmaceuticals (Inst); TESARO (Inst)
 
Anthony Shields
Consulting or Advisory Role - Caris Life Sciences; Cogent Biosciences; ImaginAb; Legend Biotech
Speakers' Bureau - Caris Life Sciences
Research Funding - Abbisko Therapeutics (Inst); Alkermes; Amal Therapeutics (Inst); Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Biomedical; Caris Life Sciences; Daiichi Sankyo; Eisai; Esperas Pharma; Esperas Pharma; Exelixis; Five Prime Therapeutics; Gritstone Bio (Inst); H3 Biomedicine; Halozyme; Hutchison China Meditech; IconOVir Bio (Inst); ImaginAb; Incyte; Inovio Pharmaceuticals; Jiangsu Alphamab Biopharmaceuticals; Lexicon; LSK BioPharma; MSK Pharma; Nouscom; Nuvation Bio (Inst); Plexxikon; Repertoire Immune Medicines; Seagen; Shanghai HaiHe Pharmaceutical; Sorrento Therapeutics (Inst); SQZ Biotechnology (Inst); Taiho Pharmaceutical; Telix Pharmaceuticals; TopAlliance BioSciences Inc (Inst); Torque (Inst); Xencor
Travel, Accommodations, Expenses - Caris Life Sciences; GE Healthcare; ImaginAb; Inovio Pharmaceuticals; TransTarget
 
Matthew Oberley
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
Travel, Accommodations, Expenses - Caris Life Sciences
 
George Sledge
Employment - Caris Life Sciences
Leadership - Caris Life Sciences; Syndax
Stock and Other Ownership Interests - Caris Life Sciences
Consulting or Advisory Role - Syndax
Travel, Accommodations, Expenses - Caris Life Sciences
 
John Paul Shen
Stock and Other Ownership Interests - Agios; Syndax; Syndax
Consulting or Advisory Role - Engine Biosciences; NaDeNo Nanosciences
Research Funding - BostonGene; Celsius Therapeutics; Celsius Therapeutics
 
Anwaar Saeed
Consulting or Advisory Role - Arcus therapeutics; Astellas Pharma; AstraZeneca; Autem therapeutics; Bristol-Myers Squibb; Exelixis; Pfizer; Taiho Pharmaceutical; Xilio therapeutics
Research Funding - Actuate Therapeutics (Inst); Arcus therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Incyte (Inst); innovent biologics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Oxford biotherapeutics (Inst); Replimune (Inst)
 
Mohamedtaki Tejani
Consulting or Advisory Role - Exelixis
Speakers' Bureau - Natera
Research Funding - Bayer (Inst)